Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00866697
Registration number
NCT00866697
Ethics application status
Date submitted
19/03/2009
Date registered
20/03/2009
Titles & IDs
Public title
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Query!
Scientific title
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Query!
Secondary ID [1]
0
0
2008-004672-50
Query!
Secondary ID [2]
0
0
110655
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ovarian Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Pazopanib
Treatment: Drugs - Placebo
Placebo comparator: Placebo - matched placebo tablet administered orally once daily for up to 24 months
Experimental: Pazopanib - Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
Treatment: Drugs: Pazopanib
Pazopanib 800 mg tablet daily for 104 weeks (24 months)
Treatment: Drugs: Placebo
Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Investigator-assessed Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is the interval between the date of randomization and the date of progression, defined by Response Evaluation Criteria in Solid Tumors (RECIST), or death due to any cause. Per RECIST, for target lesions (TLs), disease progression (PD) is defined as \>=20% increase in the sum of the longest diameters (LD) of TLs, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of \>=1 new lesions. For non-target lesions (NTLs), PD is defined as the appearance of \>=1 new lesions and/or unequivocal progression of existing NTLs. Participants (par.) who did not progress/die were censored at the date of last adequate assessment (LAA). Par. who started a new anti-cancer therapy (ACT) prior to radiological progression/death were censored at the date of LAA prior to the new ACT. Par. who progressed/died after an extended period (\>=12 months) without adequate assessment (AA) were censored at the date of their last visit with AA prior to progression/death.
Query!
Timepoint [1]
0
0
From the date of randomization until the date of progression or death due to any cause (median time of follow-up was 17.9 months for pazopanib and 12.3 months for placebo)
Query!
Secondary outcome [1]
0
0
Overall Survival - Median
Query!
Assessment method [1]
0
0
Overall surival is defined as the interval between the date of randomization and the date of death due to any cause. For participants who did not die, the time to death was censored at the time of last contact.
Query!
Timepoint [1]
0
0
From the date of randomization until the date of death due to any cause up to approximately 25 months
Query!
Secondary outcome [2]
0
0
Overall Survival: Number of Participants Experiencing Death
Query!
Assessment method [2]
0
0
Overall surival is defined as the interval between the date of randomization and the date of death due to any cause. For participants who did not die, the time to death was censored at the time of last contact.
Query!
Timepoint [2]
0
0
From the date of randomization until the date of death due to any cause up to approximately 25 months
Query!
Secondary outcome [3]
0
0
Progression-free Survival Per Gynecologic Cancer Intergroup (GCIG) Criteria
Query!
Assessment method [3]
0
0
Progression-free survival by GCIG criteria is defined as the time from the date of randomization to the earliest date of disease progression per GCIG criteria or death due to any cause. Progression is defined according to RECIST but can also be based upon serum CA-125. Progression or recurrence based on serum CA-125 levels are defined on the basis of a progressive serial elevation of serum CA-125, according to the following criteria: (1) participants (par.) with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 \>=2x the upper normal limit (UNL) on two occasions at least one week apart or; (2) par. with elevated CA-125 pretreatment, which never normalizes, must show evidence of CA-125 \>=2x the nadir value on two occasions at least one week apart or; (3) par. with CA-125 in the normal range pretreatment must show evidence of CA-125 \>=2x the UNL on two occasions at least one week apart.
Query!
Timepoint [3]
0
0
From the date of randomization until the date of progression per GCIG criteria or death due to any cause (median time of follow-up was 16.8 months for pazopanib and 11.9 months for placebo)
Query!
Secondary outcome [4]
0
0
3-year Progression-free Survival
Query!
Assessment method [4]
0
0
3-year progression-free survival is defined as the percentage of participants who are progression-free at 3 years from randomization. Progression-free survival is defined as the time from the date of randomization to the earliest date of disease progression (defined by RECIST) or death due to any cause. Per RECIST, for target lesions, disease progression (PD) is defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as a reference, the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. For non-target lesions, PD is defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Query!
Timepoint [4]
0
0
Up to 3 years after randomization
Query!
Secondary outcome [5]
0
0
Change From Baseline in the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [5]
0
0
The EORTC QLQ-C30 is a self-reported, 30-item cancer-specific instrument that assesses 15 domains: 5 functional scales (physical, role, emotional, cognitive, and social functioning), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a global health status, or quality of life. Global health status is assessed using a 7-item Likert scale, ranging from 1 to 7 ("poor" to "excellent"). Participants were asked to respond to the following questions using the 7-item Likert scale: "How would you rate your overall health during the past week"; "How would you rate your overall quality of life during the past week?" Data are transformed to a scale ranging from 0 to 100. Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures analysis of covariance (ANCOVA).
Query!
Timepoint [5]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [6]
0
0
Change From Baseline in QLQ-OV-28 Module Attitude to Disease/Treatment Functional Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [6]
0
0
The OV (ovarian)-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses attitude to disease/treatment functional symptoms, among others. Participants were asked to indicate the extent to which they experienced attention to disease/treatment functional problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: How much has your disease been a burden to you?; How much has your treatment been a burden to you?; Were you worried about your future health? Data are transformed to a scale ranging from 0 to 100. Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [6]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [7]
0
0
Change From Baseline in QLQ-OV-28 Module Body Image Functional Score on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [7]
0
0
The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses body image symptoms, among others. Participants were asked to indicate the extent to which they experienced body image problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Have you felt physically less attractive as a result of your disease or treatment?; Have you been dissatisfied with your body? Data are transformed to a scale ranging from 0 to 100. Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [7]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [8]
0
0
Change From Baseline in QLQ-OV-28 Module Peripheral Neuropathy (PN) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [8]
0
0
The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses peripheral neuropathy symptoms, among others. Participants were asked to indicate the extent to which they experienced peripheral neuropathy symptoms or problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Did you have tingling hands or feet?; Have you had numbness in your fingers or toes?; Have you felt weak in your arms or legs? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [8]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [9]
0
0
Change From Baseline in QLQ-OV-28 Module Abdominal (AB)/Gastrointestinal (GI) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [9]
0
0
The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses AB/GI symptoms, among others. Participants were asked to indicate the extent to which they experienced AB/GI symptoms or problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Did you have abdominal pain?; Did you have a bloated feeling in your abdomen/stomach?; Did you have problems with your clothes feeling too tight?; Did you experience any change in bowel habit as a result of your disease or treatment?; Were you troubled by passing wind/gas/flatulence?; Have you felt full too quickly after beginning to eat?; Have you had indigestion/heartburn? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [9]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [10]
0
0
Change From Baseline in QLQ-OV-28 Module Hormonal/Menopausal Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [10]
0
0
The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses hormonal/menopausal symptoms, among others. Participants were asked to indicate the extent to which they experienced hormonal/menopausal symptoms or problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Did you have hot flashes?; Did you have night sweats? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [10]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [11]
0
0
Change From Baseline in QLQ-OV-28 Module Sexuality Functional on Day 1 of Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [11]
0
0
The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses sexual functioning symptoms, among others. Participants were asked to indicate the extent to which they experienced sexual functioning problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: To what extent were you interested in sex?; To what extent were you sexually active?; If sexually active, to what extent was sex enjoyable for you?; If sexually active, did you have a dry vagina during sexual activity? Higher scores represent better functioning (better quality of life). Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA. Data were not analyzed due to low compliance (\<50% at Baseline).
Query!
Timepoint [11]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [12]
0
0
Change From Baseline in QLQ-OV-28 Module Other Chemotherapy Side Effects (SE) Symptoms Score at Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [12]
0
0
The OV-28 module is a 28-item addition to the EORTC QLQ-C30 that focuses on issues specific to ovarian cancer. It assesses other chemotherapy SE symptoms, among others. Participants were asked to indicate the extent to which they experienced other chemotherapy SE symptoms/problems in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following questions: Have you lost any hair?; If yes, were you upset by the loss of your hair?; Did food/drink taste different from usual?; Did you have aches or pains in your muscles or joints?; Did you have problems with hearing?; Did you urinate frequently?; Have you had skin problems (e.g., itchy, dry)? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms) for symptom scales. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA. Data were not analyzed due to low compliance (\<50% at Baseline).
Query!
Timepoint [12]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [13]
0
0
Change From Baseline in the EuroQOL EQ-5D (Five Dimensions) Thermometer Score at Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [13]
0
0
The EuroQol (EQ-5D) questionnaire is a 2-page, generic, preference-based quality of life measure comprised of a 5-item health status measure and a visual analogue scale (VAS) and is used to generate two scores: the utility score and the thermometer score The thermometer score is based on a vertical VAS. The VAS is designed like a thermometer scale on which the best health state the participant can imagine is referenced at 100, and the worst health state the participant can imagine is marked by 0. Based on how good or bad the current health state is, the participant is asked to draw a line across the thermometer scale. For example, a line drawn across 46 on the scale of 0 to 100 would be coded 46. A negative adjusted mean change from Baseline represents a worsening of quality of life. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [13]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [14]
0
0
Change From Baseline in the EQ-5D (Five Dimensions) Utility Score at Week 13 and Months 7, 10, 13, 16, and 25
Query!
Assessment method [14]
0
0
The EQ-5D utility score captures health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety and/or depression. Participants indicated the level of perceived problems in each of the five dimensions on three levels: 1, no problems; 2, some problems; 3, an extreme problem. Unique health states were defined by combining response levels from each of the five dimensions. For example, state 11111 indicates no problem on any of the five dimensions, whereas state 11223 indicates no problems with mobility or self-care; some problems with performing usual activities, moderate pain/discomfort; and extreme anxiety/depression. Responses are typically converted into health utilities or valuations on a scale ranging from 0 (worst health) to 1 (perfect health). A negative adjusted mean change from Baseline represents a worsening of quality of life. Mean changes from Baseline were calculated via mixed model-repeated measures ANCOVA.
Query!
Timepoint [14]
0
0
Baseline; Week 13; Months 7, 10, 13, 16, and 25
Query!
Secondary outcome [15]
0
0
Number of Participants With the Indicated Grade 2, 3, and 4 On-therapy Adverse Events Occurring in >=10% of Participants in Either Treatment Arm
Query!
Assessment method [15]
0
0
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were graded according to the Common Terminiology Criteria for Adverse Events (CTCAE), Version 4.0. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life threatening; Grade 5, death.
Query!
Timepoint [15]
0
0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Query!
Secondary outcome [16]
0
0
Number of Participants With the Indicated On-therapy Hematology Grade Shifts From Baseline Grade
Query!
Assessment method [16]
0
0
Hematology toxicities were graded according to the Common Terminiology Criteria for Adverse Events (CTCAE), Version 4.0. Grade refers to the severity of the toxicity. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life threatening; Grade 5, death. Participants with a missing Baseline grade were assumed to have a Baseline grade of 0. WBC=White blood cell.
Query!
Timepoint [16]
0
0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Query!
Secondary outcome [17]
0
0
Number of Participants With the Indicated On-therapy Chemistry Grade Shifts From Baseline Grade
Query!
Assessment method [17]
0
0
Hematology toxicities were graded according to the Common Terminiology Criteria for Adverse Events (CTCAE), Version 4.0. Grade refers to the severity of the toxicity. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each toxicity based on this general guideline: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, life threatening; Grade 5, death. Participants with a missing Baseline grade were assumed to have a Baseline grade of 0.
Query!
Timepoint [17]
0
0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Query!
Secondary outcome [18]
0
0
Number of Participants With the Indicated Treatment-emergent Thyroid-stimulating Hormone (TSH) Elevations Above 5 Million Units Per Liter (MU/L)
Query!
Assessment method [18]
0
0
Participants were assessed for thyroid function abnormalities. Clinical hypothyroidism is defined as 5 \<TSH \<=10 MU/L and T4 \<lower limit of normal (LLN).
Query!
Timepoint [18]
0
0
From the date of the first dose of study drug to the date of the last dose plus 28 days (average of 9.8 months for pazopanib and 12.6 months for placebo)
Query!
Eligibility
Key inclusion criteria
* written informed consent
* At least 18 years old.
* Histologically confirmed, FIGO stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma that was treated with surgical debulking and at least five cycles of platinum-taxane doublet chemotherapy.
* Study randomization at least 3 weeks and not more than 12 weeks from the date of the last chemotherapy dose, and all major toxicities from the previous chemotherapy must have resolved.
* No evidence of disease progression
* ECOG status of 0 or 2
* Able to swallow and retain oral medication.
* Adequate hematologic, hepatic, and renal system function as follows:
Hematologic
* Absolute neutrophil count (ANC) at least 1.5 X 10^9/L
* Hemoglobin at least 9 g/dL (or 5.59 mmol/L)
* Platelets at least 100 X 10^9/L
* Prothrombin time (PT) or international normalized ratio (INR) up to 1.2 X ULN
* Activated partial thromboplastin time (aPTT) up to 1.2 X ULN Hepatic
* Total bilirubin up to 1.5 X ULN
* AST and ALT up to 2.5 X ULN Renal
* Serum creatinine up to 1.5 mg/dL
Or, if greater than 1.5 mg/dL:
Calculated creatinine clearance at least 50 mL/min Urine Protein
* Urine protein is 0, trace, or +1 determined by dipstick urinalysis, or < 1.0 gram determined by 24- hour urine protein analysis.
* Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Either (a) bulky disease, or (b) any residual disease which in the opinion of the investigator will need imminent second-line therapy
* Synchronous primary endometrial carcinoma, or a past history of primary endometrial carcinoma, are excluded unless certain conditions are met.
* Clinically significant gastrointestinal abnormalities
* Prolongation of corrected QT interval (QTc) > 480 msecs
* History of any one or more cardiovascular conditions within the past 6 months prior to randomization
* Cardiac angioplasty or stenting
* Myocardial infarction
* Unstable angina
* Symptomatic peripheral vascular disease
* Class III or IV congestive heart failure
* Poorly controlled hypertension
* History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months prior to randomization
* Major surgery (including interval debulking) or trauma within 28 days, or minor surgical procedures within 7 days, prior to randomization, or has any non-healing wound, fracture, or ulcer.
* Evidence of active bleeding or bleeding diathesis.
* Hemoptysis within 6 weeks prior to randomization.
* Endobronchial metastases.
* Serious and/or unstable pre-existing medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
* Investigational or anti-VEGF anticancer therapy prior to study randomization.
* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
* Invasive malignancies that showed activity of disease within 5 years prior to randomization
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/05/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/08/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
940
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Camperdown
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Liverpool
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Randwick
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Waratah
Query!
Recruitment hospital [5]
0
0
Novartis Investigative Site - Herston
Query!
Recruitment hospital [6]
0
0
Novartis Investigative Site - South Brisbane
Query!
Recruitment hospital [7]
0
0
Novartis Investigative Site - Adelaide
Query!
Recruitment hospital [8]
0
0
Novartis Investigative Site - Hobart
Query!
Recruitment hospital [9]
0
0
Novartis Investigative Site - Malvern
Query!
Recruitment hospital [10]
0
0
Novartis Investigative Site - Parkville
Query!
Recruitment hospital [11]
0
0
Novartis Investigative Site - Wodonga
Query!
Recruitment hospital [12]
0
0
Novartis Investigative Site - Nedlands
Query!
Recruitment hospital [13]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [3]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [4]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [5]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [6]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [7]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [8]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [9]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [10]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [11]
0
0
3690 - Wodonga
Query!
Recruitment postcode(s) [12]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [13]
0
0
3084 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New Jersey
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Virginia
Query!
Country [7]
0
0
Austria
Query!
State/province [7]
0
0
Graz
Query!
Country [8]
0
0
Austria
Query!
State/province [8]
0
0
Innsbruck
Query!
Country [9]
0
0
Austria
Query!
State/province [9]
0
0
Klagenfurt Am Woerthersee
Query!
Country [10]
0
0
Austria
Query!
State/province [10]
0
0
Korneuburg
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Krems
Query!
Country [12]
0
0
Austria
Query!
State/province [12]
0
0
Leoben
Query!
Country [13]
0
0
Austria
Query!
State/province [13]
0
0
Linz
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Oberpullendorf
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Wien
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Bonheiden
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Duffel
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Gent
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Kortrijk
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Libramont
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Liege
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Namur
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Oostende
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Guangdong
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Jiangsu
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Liaoning
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Shandong
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Zhejiang
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Beijing
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Shanghai
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Tianjin
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Aalborg
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
Herlev
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Herning
Query!
Country [36]
0
0
Denmark
Query!
State/province [36]
0
0
Koebenhavn Oe
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
ANGERS Cedex 2
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Avignon cedex
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Besancon Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bordeaux
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Bourg en Bresse Cedex
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Brest Cedex
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Brive La Gaillarde
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Caen Cedex 05
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Clermont-Ferrand cedex
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Colmar Cedex
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Dax Cedex
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Grenoble Cedex 09
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Grenoble Cedex
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
La Roche sur Yon Cedex 9
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Le Chesnay Cedex
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Le Mans
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Lille Cedex
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Lille
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Lorient cedex
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Lyon Cedex 08
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Marseille cedex
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Metz Cedex 03
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Mont de Marsan
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Montpellier cedex 5
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Montpellier
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Mougins Cedex 2
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Nancy
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Nantes Cedex 2
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Nice Cedex 2
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
Nimes
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Orleans
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Paris cedex 05
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Paris Cedex 10
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Paris Cedex 20
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Paris Cedex 4
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Paris
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Perigueux Cedex
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Perin Sur Mer
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Pierre-Benite Cedex
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Reims Cedex
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Rouen
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Saint-Herblain
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Saint-Priest en Jarez
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Strasbourg Cedex
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Strasbourg
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Suresnes
Query!
Country [83]
0
0
France
Query!
State/province [83]
0
0
Thonon-les-Bains
Query!
Country [84]
0
0
France
Query!
State/province [84]
0
0
Vandoeuvre-Les-Nancy
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Baden-Wuerttemberg
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Bayern
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Hessen
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Mecklenburg-Vorpommern
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Niedersachsen
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Nordrhein-Westfalen
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Rheinland-Pfalz
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Sachsen-Anhalt
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Sachsen
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Schleswig-Holstein
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Thueringen
Query!
Country [96]
0
0
Germany
Query!
State/province [96]
0
0
Berlin
Query!
Country [97]
0
0
Germany
Query!
State/province [97]
0
0
Hamburg
Query!
Country [98]
0
0
Hong Kong
Query!
State/province [98]
0
0
Hong Kong
Query!
Country [99]
0
0
Hong Kong
Query!
State/province [99]
0
0
Kowloon
Query!
Country [100]
0
0
Ireland
Query!
State/province [100]
0
0
Dublin
Query!
Country [101]
0
0
Ireland
Query!
State/province [101]
0
0
Waterford
Query!
Country [102]
0
0
Ireland
Query!
State/province [102]
0
0
Wilton, Cork
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Basilicata
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Campania
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Emilia-Romagna
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Friuli-Venezia-Giulia
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Lazio
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Lombardia
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Molise
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Piemonte
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Puglia
Query!
Country [112]
0
0
Italy
Query!
State/province [112]
0
0
Sicilia
Query!
Country [113]
0
0
Italy
Query!
State/province [113]
0
0
Umbria
Query!
Country [114]
0
0
Italy
Query!
State/province [114]
0
0
Veneto
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Ehime
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Fukuoka
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Hiroshima
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Hokkaido
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Iwate
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Kagoshima
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Miyagi
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Osaka
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Saitama
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Tokyo
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Tottori
Query!
Country [126]
0
0
Korea, Republic of
Query!
State/province [126]
0
0
Goyang-si, Gyeonggi-do
Query!
Country [127]
0
0
Korea, Republic of
Query!
State/province [127]
0
0
Kangnam-Ku ,Seoul
Query!
Country [128]
0
0
Korea, Republic of
Query!
State/province [128]
0
0
Seoul
Query!
Country [129]
0
0
Norway
Query!
State/province [129]
0
0
Bergen
Query!
Country [130]
0
0
Norway
Query!
State/province [130]
0
0
Oslo
Query!
Country [131]
0
0
Norway
Query!
State/province [131]
0
0
Stavanger
Query!
Country [132]
0
0
Norway
Query!
State/province [132]
0
0
Tromso
Query!
Country [133]
0
0
Spain
Query!
State/province [133]
0
0
Alcorcon (Madrid)
Query!
Country [134]
0
0
Spain
Query!
State/province [134]
0
0
Barcelona
Query!
Country [135]
0
0
Spain
Query!
State/province [135]
0
0
Cartagena (Murcia)
Query!
Country [136]
0
0
Spain
Query!
State/province [136]
0
0
Elche
Query!
Country [137]
0
0
Spain
Query!
State/province [137]
0
0
Lerida
Query!
Country [138]
0
0
Spain
Query!
State/province [138]
0
0
Madrid
Query!
Country [139]
0
0
Spain
Query!
State/province [139]
0
0
Murcia (El Palmar)
Query!
Country [140]
0
0
Spain
Query!
State/province [140]
0
0
Palma de Mallorca
Query!
Country [141]
0
0
Spain
Query!
State/province [141]
0
0
Pamplona
Query!
Country [142]
0
0
Spain
Query!
State/province [142]
0
0
Sabadell (Barcelona)
Query!
Country [143]
0
0
Spain
Query!
State/province [143]
0
0
San Sebastian
Query!
Country [144]
0
0
Spain
Query!
State/province [144]
0
0
Santiago de Compostela
Query!
Country [145]
0
0
Spain
Query!
State/province [145]
0
0
Terrassa
Query!
Country [146]
0
0
Spain
Query!
State/province [146]
0
0
Valencia
Query!
Country [147]
0
0
Spain
Query!
State/province [147]
0
0
Zaragoza
Query!
Country [148]
0
0
Sweden
Query!
State/province [148]
0
0
Linkoping
Query!
Country [149]
0
0
Sweden
Query!
State/province [149]
0
0
Lund
Query!
Country [150]
0
0
Sweden
Query!
State/province [150]
0
0
Stockholm
Query!
Country [151]
0
0
Sweden
Query!
State/province [151]
0
0
Uppsala
Query!
Country [152]
0
0
Taiwan
Query!
State/province [152]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
GlaxoSmithKline
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00866697
Query!
Trial related presentations / publications
Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. doi: 10.1016/j.ygyno.2019.08.024. Epub 2019 Sep 10. Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy. Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796. Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Med Ethics. 2016 Oct 21;17(1):63. doi: 10.1186/s12910-016-0144-y. Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. doi: 10.1097/IGC.0000000000000602. Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A. Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
Query!
No/undecided IPD sharing reason/comment
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/97/NCT00866697/SAP_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00866697